Is the recreational use of MDMA related to the prevalence of toxic cardiac valvulopathy? A cross sectional study between non-, incidental and heavy MDMA users.

Is the recreational use of MDMA related to the prevalence of toxic cardiac valvulopathy? A cross sectional study between non-, incidental and heavy MDMA users. - The prevalence of toxic cardiac valvulopathy in MDMA users

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52054

Enrollment

240

Registered

2022-06-07

Start date

2022-04-01

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Valve disease Valvulopathy

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Group 1 (heavy users): circa 1100 pills (+- 200) in a life time Group 2 (moderate users): circa 550 pills (+- 100) in a life time Group 3 (never users): never users

Exclusion criteria

Exclusion criteria: Age

Design outcomes

Primary

Measure	Time frame
Moderate to severe valvular regurgitation (futher defined as secondary outcomes)	—

Secondary

Measure	Time frame
- Prevalance of heart valve abnormalities (valvulopathy) in group 1 (heavy users) and group 2 (moderate users) compared to group 3 (non-users): - Moderate aortic regurgitation - Severe aortic regurgtitation - Moderate aortic stenosis - Severe aortic stenosis - Moderate mitral regurgitation, - Severe mitral regurgitation - Moderate mitral stenosis - Severe mitral stenosis - Moderate pulmonary regurgitation - Severe pulmonary regurgitation - Moderate pulmonary regurgitation - Severe pulmonary stenosis - Moderate pulmonary stenosis - Moderate tricuspid regurgitation, - Severe tricuspid regurgitation - Moderate tricuspid stenosis - Severe tricuspid stenosis Confirmation of the hypothesis that heavy use holds a higher risk for heart valve abnormalities (in line with previous studies)	—

Measure

Time frame

- Prevalance of heart valve abnormalities (valvulopathy) in group 1 (heavy users) and group 2 (moderate users) compared to group 3 (non-users): - Moderate aortic regurgitation - Severe aortic regurgtitation - Moderate aortic stenosis - Severe aortic stenosis - Moderate mitral regurgitation, - Severe mitral regurgitation - Moderate mitral stenosis - Severe mitral stenosis - Moderate pulmonary regurgitation - Severe pulmonary regurgitation - Moderate pulmonary regurgitation - Severe pulmonary stenosis - Moderate pulmonary stenosis - Moderate tricuspid regurgitation, - Severe tricuspid regurgitation - Moderate tricuspid stenosis - Severe tricuspid stenosis Confirmation of the hypothesis that heavy use holds a higher risk for heart valve abnormalities (in line with previous studies)

—

Countries

Netherlands

Outcome results